Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year Low – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares reached a new 52-week low during trading on Wednesday . The stock traded as low as $18.00 and last traded at $18.05, with a volume of 6643 shares trading hands. The stock had previously closed at $18.29.

Analysts Set New Price Targets

DNTH has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. TD Cowen assumed coverage on Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Guggenheim reaffirmed a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Wedbush reiterated an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Dianthus Therapeutics presently has an average rating of “Buy” and an average price target of $54.33.

Dianthus Therapeutics Stock Performance

The firm has a fifty day moving average price of $21.94 and a 200 day moving average price of $24.42. The company has a market cap of $576.48 million, a price-to-earnings ratio of -7.18 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The firm had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Quest Partners LLC lifted its holdings in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Dianthus Therapeutics by 142.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after buying an additional 97,362 shares in the last quarter. MetLife Investment Management LLC boosted its position in shares of Dianthus Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock valued at $382,000 after acquiring an additional 7,854 shares during the period. Walleye Capital LLC acquired a new position in shares of Dianthus Therapeutics in the third quarter valued at about $821,000. Finally, Braidwell LP grew its stake in shares of Dianthus Therapeutics by 34.6% in the third quarter. Braidwell LP now owns 493,687 shares of the company’s stock valued at $13,517,000 after acquiring an additional 126,836 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.